Rate Video

SOHO 2020 | Spleen volume responses in fedratinib treated myelofibrosis patients

Ruben Mesa • 1 Sep 2020

Myelofibrosis Myeloproliferative Neoplasms Fedratinib

JAKARTA JAKARTA2

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the spleen volume responses as assessed in the JAKARTA study (NCT01437787), where patients with myelofibrosis were treated with fedratinib, a JAK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Design and results of PERSIST-1 trial of pacritinib for myelofibrosis

Ruben Mesa • 2 Jun 2015

Pilot study of ropeginterferon in early myelofibrosis

Ruben Mesa • 1 Dec 2020

Key takeaways from the Texas MPN Workshop 2020

Ruben Mesa • 31 Aug 2020

The importance of diversity to the success of clinical research

Ruben Mesa • 1 Dec 2020

Related Videos

ESH CML/MPNs 2021: what to expect?

Ruben Mesa • 17 Feb 2021

Transplantation in MF: patient-centered communication and decision making

Ruben Mesa • 17 Feb 2021

Transplantation in patients with myelofibrosis

Ruben Mesa • 17 Feb 2021

Haploidentical vs matched donor transplantation in patients with myelofibrosis

Tania Jain • 12 Feb 2021